Perspective Therapeutics, INC. (CATX) — SEC Filings

Overview

Perspective Therapeutics, INC. (CATX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: Perspective Therapeutics, Inc. filed an 8-K on April 20, 2026, reporting other events. The filing includes various exhibits, such as financial statements and graphics, but does not detail specific transactions or financial figures within the provided text.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Perspective Therapeutics, INC. is neutral.

Filing Type Overview

Perspective Therapeutics, INC. (CATX) has filed 36 8-K, 5 10-Q, 1 DEF 14A, 1 10-K/A, 2 SC 13G/A, 4 SC 13G, 1 8-K/A with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Perspective Therapeutics Files 8-K — 8-K · Apr 20, 2026 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on April 20, 2026, reporting other events. The filing includes various exhibits, such as financial statements and gr
• Perspective Therapeutics Files 8-K — 8-K · Dec 1, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on December 1, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., i
• CATX Q3 Loss Widens on Soaring R&D Costs, Cash Drains — 10-Q · Nov 10, 2025 Risk: high
  Perspective Therapeutics, Inc. (CATX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $65.631 million, compar
• Perspective Therapeutics Files 8-K — 8-K · Nov 6, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on November 6, 2025, reporting on other events and financial statements. The company, formerly known as Isoray, Inc.
• Perspective Therapeutics Names New Directors, CMO Departs — 8-K · Nov 3, 2025 Risk: medium
  Perspective Therapeutics, Inc. announced on November 3, 2025, the departure of its Chief Medical Officer, Dr. Michael L. Lavoie. The company also reported the e
• Perspective Therapeutics Files 8-K — 8-K · Oct 20, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on October 20, 2025, reporting on its results of operations and financial condition, other events, and financial sta
• 8-K Filing — 8-K · Oct 1, 2025
• Perspective Therapeutics Files 8-K on Officer/Director Changes — 8-K · Sep 4, 2025 Risk: medium
  Perspective Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting events as of September 2, 2025. The filing includes information regarding the depart
• Perspective Therapeutics Files 8-K: Board, Officer, and Compensation Updates — 8-K · Sep 3, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting changes in its board of directors and officers, along with details on compensatory a
• Perspective Therapeutics Files 8-K — 8-K · Sep 2, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on September 2, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc.,
• CATX R&D Surge Drives Q2 Loss to $21.5M Amid Cash Burn — 10-Q · Aug 13, 2025 Risk: high
  Perspective Therapeutics, Inc. (CATX) reported a significant increase in net loss for the three and six months ended June 30, 2025, primarily driven by a substa
• 8-K Filing — 8-K · Aug 1, 2025
• Perspective Therapeutics Files 8-K — 8-K · Jul 3, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on July 3, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., is in
• 8-K Filing — 8-K · Jun 23, 2025
• Perspective Therapeutics Files 8-K — 8-K · Jun 3, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., is in
• Perspective Therapeutics Files 8-K — 8-K · May 30, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on other events and financial statements. The company, formerly known as Isoray, Inc., is
• Perspective Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 28, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on May 28, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain detai
• Perspective Therapeutics Files 10-Q, Reveals Past Names — 10-Q · May 12, 2025 Risk: low
  Perspective Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing indicates the company's fiscal year ends on December 31st. Previo
• Perspective Therapeutics Files 8-K — 8-K · May 1, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on May 1, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., is inc
• Perspective Therapeutics Files 8-K — 8-K · Apr 29, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on April 29, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., is
• Perspective Therapeutics Files DEF 14A for 2024 — DEF 14A · Apr 16, 2025 Risk: low
  Perspective Therapeutics, Inc. (formerly Isoray, Inc.) filed a DEF 14A on April 16, 2025, for the fiscal year ending December 31, 2024. The filing details execu
• Perspective Therapeutics Files 8-K — 8-K · Apr 11, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on April 11, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., is
• Perspective Therapeutics Files 2024 Annual Report Amendment — 10-K/A · Mar 28, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2024. The filing, submitted on March 28,
• 8-K Filing — 8-K · Mar 26, 2025
• Perspective Therapeutics Files 8-K — 8-K · Mar 17, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on March 17, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as
• Perspective Therapeutics, Inc. Files 8-K — 8-K · Mar 4, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on March 4, 2025, reporting an event on March 3, 2025. The filing indicates a change in the company's name from Isor
• Perspective Therapeutics Files 8-K — 8-K · Feb 3, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on February 3, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., i
• Perspective Therapeutics Files 8-K — 8-K · Jan 24, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on January 24, 2025, reporting on other events and financial statements. The company, formerly known as Isoray, Inc.
• Perspective Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events. The fi
• Perspective Therapeutics Appoints New Chief Medical Officer — 8-K · Jan 6, 2025 Risk: medium
  Perspective Therapeutics, Inc. announced on January 2, 2025, the appointment of Dr. Jonathan M. Roth as Chief Medical Officer. Dr. Roth previously served as Chi
• Perspective Therapeutics Files 8-K — 8-K · Dec 4, 2024 Risk: medium
  Perspective Therapeutics, Inc. (formerly Isoray, Inc.) filed an 8-K on December 4, 2024, reporting an event on December 3, 2024. The filing indicates a change i
• Perspective Therapeutics Files 8-K — 8-K · Nov 21, 2024 Risk: low
  Perspective Therapeutics, Inc. (formerly IsoRay, Inc.) filed an 8-K on November 21, 2024, reporting other events and financial statements. The company, incorpor
• Perspective Therapeutics Files 8-K — 8-K · Nov 15, 2024 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on November 15, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Perspective Therapeutics Files Q3 10-Q, Cites Key Agreements — 10-Q · Nov 12, 2024 Risk: medium
  Perspective Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Isoray, Inc., is in the surgical and medi
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 7, 2024
• SC 13G Filing — SC 13G · Oct 24, 2024
• Perspective Therapeutics Files 8-K — 8-K · Oct 11, 2024 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K on October 11, 2024, reporting other events and financial statements. The company, formerly known as Isoray, Inc., i
• Perspective Therapeutics Completes Asset Acquisition — 8-K · Sep 20, 2024 Risk: medium
  Perspective Therapeutics, Inc. announced on September 18, 2024, the completion of its acquisition of certain assets. The company also entered into a material de
• Perspective Therapeutics to Acquire Radiactiv, Inc. — 8-K · Sep 5, 2024 Risk: medium
  Perspective Therapeutics, Inc. announced on September 5, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Radiactiv, I
• Perspective Therapeutics Appoints New CMO, Director — 8-K · Aug 30, 2024 Risk: medium
  Perspective Therapeutics, Inc. announced on August 26, 2024, the appointment of Dr. Jonathan M. Roth as Chief Medical Officer and the election of Ms. Jennifer L
• Perspective Therapeutics Adds Medical Device Veteran to Board — 8-K · Aug 19, 2024 Risk: low
  Perspective Therapeutics, Inc. announced on August 16, 2024, the election of Dr. David W. Schramm to its Board of Directors. Dr. Schramm brings extensive experi
• Perspective Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Perspective Therapeutics, Inc. (formerly Isoray, Inc.) filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operatio
• Perspective Therapeutics Files 8-K/A Amendment — 8-K/A · Aug 12, 2024 Risk: low
  Perspective Therapeutics, Inc. filed an 8-K/A on August 12, 2024, to amend a previous filing. The amendment pertains to the company's results of operations and
• Perspective Therapeutics to Acquire Subsidiary IsoRay Medical — 8-K · Jun 14, 2024 Risk: low
  Perspective Therapeutics, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of its subsidiary,
• Perspective Therapeutics Files 8-K on Officer/Director Changes — 8-K · May 31, 2024 Risk: medium
  Perspective Therapeutics, Inc. filed an 8-K on May 31, 2024, reporting on several key events. These include the departure of directors or certain officers, the
• Perspective Therapeutics Enters Material Definitive Agreement — 8-K · May 29, 2024 Risk: medium
  Perspective Therapeutics, Inc. announced on May 24, 2024, that it entered into a material definitive agreement. The company, formerly known as Isoray, Inc., is

Related Companies

PTX

Frequently Asked Questions